Cell Therapeutics agrees to market 15.

Related StoriesInner ear damage mind warnings from nerve cellsScalable production of gene therapy vectors: an interview with Frank UbagsHPV analysis partnership signed between Beckman Coulter and IncellDx Each talk about of Series 18 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time before the automatic conversion of such shares in certain circumstances, into a total of 15 million shares of authorized common share at a conversion cost of $1.00 per share of common stock.. Cell Therapeutics agrees to market 15,000 shares of Series 18 Preferred Share to Quogue Capital Cell Therapeutics, Inc.Karagas, Ph.D., professor in the Section of Community and Family members Medicine at Dartmouth Medical College. We provide important insight in to the etiology of arsenic-induced disease, potentially highly relevant to the millions of people worldwide who face arsenic, she stated. Related StoriesCrucial change in single DNA base predisposes kids to aggressive form of cancerViralytics enters into clinical trial collaboration contract with MSDFDA grants accelerated acceptance for Tagrisso to treat individuals with advanced NSCLCArsenic can be a well-known environmental toxin and carcinogen.